The NMA included six treatment regimens for advanced ESCC patients with varying PD-L1 expression levels (Figure 4C) to evaluate the efficacy of these treatments in patients with positive PD-L1 expression. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.